Comparative Pharmacology
Head-to-head clinical analysis: DESLORATADINE versus TELDRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESLORATADINE versus TELDRIN.
DESLORATADINE vs TELDRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desloratadine is a long-acting tricyclic histamine antagonist selective for the H1 receptor, inhibiting histamine release from mast cells and basophils. It reduces allergic inflammation by decreasing cytokine and chemokine release.
TELDRIN contains loratadine and pseudoephedrine. Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1-receptor antagonism. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction.
5 mg orally once daily.
1-2 mg orally twice daily; maximum 4 mg/day.
None Documented
None Documented
Clinical Note
moderateDesloratadine + Venlafaxine
"The risk or severity of adverse effects can be increased when Desloratadine is combined with Venlafaxine."
Clinical Note
moderateDesloratadine + Nefazodone
"The risk or severity of adverse effects can be increased when Desloratadine is combined with Nefazodone."
Clinical Note
moderateDesloratadine + Stiripentol
"The risk or severity of adverse effects can be increased when Desloratadine is combined with Stiripentol."
Clinical Note
moderateTerminal half-life 27 hours (range 21–30 h) in healthy adults; supports once-daily dosing.
Terminal half-life: 9-12 hours (range 8-14) in healthy adults; prolonged in renal impairment.
Primarily renal (87% as metabolites, ~41% unchanged) and fecal (~9%). Metabolized to active 3-hydroxydesloratadine.
Renal: 55-60% unchanged; fecal: 35-40%; minor biliary elimination.
Category A/B
Category C
Antihistamine
Antihistamine
Desloratadine + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Desloratadine."